Rare and Genetic Disease Network

Featured

Fibromuscular Dysplasia (FMD): Diagnosing and Treating this Rare Disorder

Ido Weinberg, MD, Medical Director, VASCORE; Assistant Professor of Medicine at Harvard Medical School, Co-Medical Director, Anticoagulation Management Services, Massachusetts General Hospital, discusses diagnostic challenges of treatment limitations of Fibromuscular Dysplasia (FMD).

Management and Treatment of Spontaneous Coronary Artery Dissection (SCAD)

Malissa J. Wood, MD, is co-director of the Corrigan Women’s Heart Health Program at Massachusetts General Hospital and associate professor of medicine at Harvard Medical School. In this video, Dr. Wood discusses the management and treatment of Spontaneous Coronary Artery Dissection (SCAD).

Differential Diagnosis of Mucopolysaccharidosis Type I (MPS 1)

Heather A. Lau, MD, Director, Lysosomal Storage Disease Program at NYU Langone Health discusses the differential diagnosis of Mucopolysaccharidosis type I (MPS I), a condition that affects many parts of the body. MPS I is a condition that affects many parts of the body.

Fibromuscular Dysplasia and the “String of Beads”

Jeffrey W Olin, DO, Professor of Medicine at the Icahn School of Medicine at Mount Sinai, discusses the “string of beads” as the description typically given to the appearance of the renal artery in fibromuscular dysplasia (FMD).

Solid Biosciences and the Role of Advocates

Ilan Ganot, Co-Founder, President and CEO of Solid Biosciences discusses how his company views advocates and patients who have Duchenne muscular dystrophy (DMD). Mr. Ganot started Solid in 2013 to find treatments, and potentially a cure, for DMD, a disease that afflicts his son Eytani.

American Porphyria Foundation’s Focus on Physician Education

Kristen Wheeden, Director of Development for the American Porphyria Foundation, provides an overview of her foundation and it’s focus on physician education. The American Porphyria Foundation is also dedicated to the health and well-being of patient and families impacted by Porphyria.

Gene Therapy Will Get Less Expensive

As Dr. Brown explains in this video, gene therapy is ideal suited for many rare diseases since most rare diseases have a genetic origin. But with 6000 – 7000 known rare diseases and with gene therapy costing over $1 million a therapy, the cost of developing gene therapy for many of the 30 million Americans with a rare condition is not sustainable.

PTC Therapeutics Company Overview

Mark Pykett, PhD, Chief Scientific Officer at PTC Therapeutics, provides an overview of his company, including its focus on rare diseases.

iSCAD Registry

Malissa J. Wood, MD at Harvard Medical School discusses the iSCAD Registry, which develops and maintains an independent, multi-center data repository to advance the pace and breadth of SCAD research around the world. Spontaneous coronary artery dissection (SCAD) is a rare condition and occurs when a tear forms in one of the blood vessels in the heart.

Differences in FMD in Men and Women and Exploring the SCAD Connection

Ido Weinberg, MD, Medical Director, VASCORE; Assistant Professor of Medicine Harvard Medical School, Co-Medical Director, Anticoagulation Management Services, Massachusetts General Hospital, discusses Fibromuscular Dysplasia (FMD) in men and women and its relationship to Spontaneous Coronary Artery Dissection (SCAD).

Special Reports